A settlement between GlaxoSmithKline and a number of U.S. states will give New Jersey approximately $2.45 million, acting Attorney General John J. Hoffman announced Wednesday.
New Jersey is part of a multistate settlement involving the promotion of the asthma drug Advair and antidepressants Paxil and Wellbutrin. The states had alleged GlaxoSmithKline illegally promoted the drugs for unapproved uses.
“The marketing and promotion of pharmaceutical products for unapproved uses is unlawful and potentially harmful, as is misrepresenting the efficacy of any drug,” Hoffman said in a statement. “This settlement is important to protecting New Jersey consumers because it calls for the use of only clear, objective, well-supported clinical information in the promotion of these GlaxoSmithKline medications.”
ALSO ON NJBIZ:
Please note: All comments will be reviewed and may take up to 24 hours to appear on the site.View Comment Policy